BIOMAT Database Logo BIOMAT Database Logo

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. 2012

A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
Department of Pathology, Duke University Medical Center, Research Drive, Box 3455 DUMC, Durham, NC, USA.

BACKGROUND In early-stage breast cancer, adjuvant chemotherapy is associated with significant systemic toxicity with only a modest survival benefit. Therefore, there is considerable interest in identifying predictive markers of response to therapy. Doxorubicin, one of the most common drugs used to treat breast cancer, is an anthracycline chemotherapeutic agent, a class of drugs known to be affected by hypoxia. Accordingly, we examined whether expression of the endogenous hypoxia marker carbonic anhydrase IX (CA IX) is predictive of outcome in early-stage breast cancer patients treated with doxorubicin. METHODS We obtained 209 early-stage pre-treatment surgically-resected breast tumours from patients, who received doxorubicin in their chemotherapeutic regimen and had >10 years of follow-up. Immunohistochemistry was used to detect CA IX, and we used fluorescence in situ hybridisation to detect both human epidermal growth factor receptor (HER2) and DNA topoisomerase II-alpha (TOP2A) gene amplification. RESULTS Carbonic anhydrase IX intensity was significantly correlated with progression-free survival (PFS) and overall survival (OS) in patients receiving 300 mg m(-2) of doxorubicin (HR=1.82 and 3.77; P=0.0014 and 0.010, respectively). There was a significant, inverse correlation between CA IX score and oestrogen receptor expression, but no significant correlations were seen with either HER2 or TOP2A ratio. CONCLUSIONS We demonstrate that CA IX expression is correlated with worse PFS and OS for breast cancer patients treated with doxorubicin, independent of HER2 or TOP2A gene amplification. This study provides evidence that using CA IX to detect hypoxia in surgically-resected breast tumours may be of clinical use in choosing an appropriate chemotherapy regimen.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002256 Carbonic Anhydrases A family of zinc-containing enzymes that catalyze the reversible hydration of carbon dioxide. They play an important role in the transport of CARBON DIOXIDE from the tissues to the LUNG. EC 4.2.1.1. Carbonate Dehydratase,Carbonic Anhydrase,Anhydrases, Carbonic,Dehydratase, Carbonate
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071231 Carbonic Anhydrase IX A carbonic anhydrase and transmembrane protein that consists of an N-terminal PROTEOGLYCAN-like domain, a catalytic region, a single-pass transmembrane domain, and a short intracellular tail. It functions as a dimer and is expressed primarily by cells of the GASTROINTESTINAL TRACT; BILE DUCT EPITHELIUM; and GALL BLADDER. It is expressed at high levels in many solid tumors, especially CLEAR CELL RENAL CARCINOMA, in response to CELL HYPOXIA. CAIX Protein,Carbonic Anhydrase 9

Related Publications

A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer.
April 2007, British journal of cancer,
A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
September 2012, Breast cancer research and treatment,
A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
Carbonic anhydrase IX in early-stage non-small cell lung cancer.
December 2004, Clinical cancer research : an official journal of the American Association for Cancer Research,
A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.
August 2011, Virchows Archiv : an international journal of pathology,
A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.
January 2017, Medicine,
A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
Overexpression of Carbonic Anhydrase IX is a Dismal Prognostic Marker in Breast Carcinoma in Egyptian Patients.
July 2016, Applied immunohistochemistry & molecular morphology : AIMM,
A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer.
June 2022, Breast cancer research : BCR,
A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
January 2016, Disease markers,
A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
August 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A S Betof, and Z N Rabbani, and M E Hardee, and S J Kim, and G Broadwater, and R C Bentley, and S A Snyder, and Z Vujaskovic, and E Oosterwijk, and L N Harris, and J K Horton, and M W Dewhirst, and K L Blackwell
Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
April 2009, Cancer,
Copied contents to your clipboard!